施普善（脑活素）对急性缺血性卒中的临床疗效研究  

Efficacy of cerebrolysin on patients with acute cerebral infarction

作　　者：万志荣[1] 李继来[1] 杜继臣[1] 

机构地区：[1]航天中心医院神经内科,北京100049

出　　处：《中华神经医学杂志》2011年第11期1181-1183,共3页Chinese Journal of Neuromedicine

摘　　要：目的观察施普善治疗急性缺血性卒中的疗效和安全性。方法采用开放、随机、对照研究，选择航天中心医院神经内科自2008年1月至2011年1月收治的发病在48h内的急性缺血性卒中患者108例，随机数字表法分成治疗组（64例）和对照组f44例），对照组给予常规治疗，治疗组在常规治疗基础上给予30mL施普善（内含于250mL氯化钠注射液），连续14d。依据美国国立卫生院卒中量表（NIHSS）评分及日常生活能力评分（BI指数）评定患者神经功能缺损程度，并监测肝肾功能、血尿常规及心电图。结果与对照组相比，治疗组NIHSS评分、B1分值在治疗后差异均有统计学意义（P〈0．05）。结论施普善能有效改善急性缺血性卒中患者的神经功能缺损。Objective To investigate the efficacy and safety of cerebrolysin in patients with acute cerebral infarction （ACI）. Methods A randomized, open-label, controlled trial of cerebrolysin in the treatment of ACI within 48 h of onset was performed; these 108 patients were randomly divided into treatment group （n=64） and control group （n=44）; the control group was only given routine therapy and the treatment group was allocated 30 mg cerebrolysin for 14 d. Therapeutic effect was evaluated by the National institutes of Health Stroke Scale （NIHSS） and the Bathal index （BI）. The liver and renal function, levels of blood and urinary routine, and electrocardiogram （ECG） were detected. Results As compared with those in the control group, significant difference on scores of NIHSS and BI was noted in the treatment group the treatment group （P〈0.05）. Conclusion Cerebrolysin is efficacious in the treatment of AIC due to the improvement of neurological deficits of the patients.

关 键 词：脑梗死 施普善 美国国立卫生院卒中量表评分 日常生活能力评分 

分 类 号：R743.3[医药卫生—神经病学与精神病学]